Exelixis stock gets a higher Truist target at USD 54

Published on 10/08/2026 at 06:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exelixis stock's Q2 revenue reached USD 628.69 million on August 5, 2026, up 10.6 percent year over year. EPS came in at USD 0.91 versus USD 0.85.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Exelixis stock (ISIN US30161Q1040) closed at USD 58.44 on Nasdaq on October 7, 2026, up 0.19 percent from the prior close. The latest analyst action came from Truist, which raised its price target to USD 54 from USD 52 while keeping a Hold rating, according to Markets Insider on October 7, 2026.

Truist raises target to USD 54

Truist analyst Gregory Renza lifted the target by USD 2, or 3.8 percent, as the firm previewed third-quarter results and adjusted its biotechnology models. The Hold rating stayed unchanged, leaving the revised target below the October 7 closing price.

The valuation gap is also visible in the broader analyst view. MarketBeat reported a Hold consensus from 20 analysts and an average target of USD 50.29 on October 7, 2026, while the stock stood at USD 58.44.

Q2 revenue rose 10.6 percent

Exelixis generated USD 628.69 million in Q2 2026 revenue, up 10.6 percent from the same quarter a year earlier. Reported EPS was USD 0.91 against USD 0.85 consensus, a USD 0.06 beat, although revenue came in below the USD 636.40 million estimate, according to MarketBeat.

The Q2 figures keep the commercial business central to the investment case. The revenue increase supports the operating base, while the earnings comparison shows that cost and product mix helped offset the modest revenue miss against expectations.

Q3 report date is November 3

The next scheduled checkpoint is Exelixis' Q3 2026 report on November 3, 2026. MarketBeat lists consensus EPS of USD 0.88 and expected revenue of USD 647.90 million for that quarter.

Exelixis stock stays below its yearly high

Exelixis stock closed at USD 58.44 on Nasdaq on October 7, 2026, with a 52-week range of USD 33.76 to USD 61.14. Its market capitalization was USD 14.5 billion and trading volume reached 2,374,774 shares, giving investors a clear valuation reference ahead of the November report.